Anchor Investment Management LLC Has $902,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Anchor Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 212.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 858 shares of the biopharmaceutical company’s stock after buying an additional 583 shares during the quarter. Anchor Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $902,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Sachetta LLC grew its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $740.97 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20. The company’s 50-day moving average is $860.87 and its 200 day moving average is $1,007.41. The company has a market capitalization of $81.43 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 2.32 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,099.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.